Triumvira Immunologics Establishes Collaboration with Merck to Evaluate Tac01-Her2 Cell Therapy in Combination with Keytruda« (Pembrolizumab) in Patients with Her2-Positive Solid Tumors

Triumvira Immunologics, announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the U.S. and Canada). Triumvira's ongoing TACTIC-2 trial will evaluate the use of its novel autologous cell therapy TAC01-HER2 as a monotherapy but also in combination with Merck's anti-PD-1 therapy KEYTRUDA« (pembrolizumab) for the treatment of HER2-positive solid tumors. At the European Society for Medical Oncology 2022 Congress, Triumvira presented interim data from the ongoing TACTIC-2 Phase 1/2 trial that demonstrated the safety and preliminary efficacy of TAC01-HER2 in patients with HER2-positive solid tumors regardless of level of expression.

TACTIC-2 is actively enrolling participants at five clinical trial sites across the U.S. and Canada. The expansion phase of the trial is expected to launch in 2023. The trial will enroll a monotherapy arm with TAC01-HER2 and a combination therapy arm with TAC01-HER2 and KEYTRUDA, in patients with HER2-positive solid tumors.

Merck will supply Triumvira with KEYTRUDA for the trial and the two companies will form a Joint Development Committee to review the clinical trial results. More details on the Phase 1/2 TACTIC-2 trial can be found at clinicaltrials.gov using ClinicalTrials.gov Identifier NCT04727151.